327046-79-7

Basic information

• Product Name: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester;N-(4-BroMo-2-nitrophenyl)carbaMic Acid tert-Butyl Ester;tert-butyl (4-bromo-2-nitrophenyl)carbamate;(4-Bromo-2-nitro-phenyl)-carbamic acid tert-butyl ester
• CAS NO: 327046-79-7
• Molecular Formula: C₁₁H₁₃BrN₂O₄
• Molecular Weight: 317.13592
• Product Categories: Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 327046-79-7.mol
• Article Data: 33

Chemical Properties

• Boiling Point: 337.8±32.0 °C(Predicted)
• Appearance: /
• Density: 1.535±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform, Dichloromethane, Methanol
• PKA: 11.70±0.70(Predicted)
• CAS DataBase Reference: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester(327046-79-7)
• EPA Substance Registry System: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester(327046-79-7)

Safety Data

• Hazardous Substances Data: 327046-79-7(Hazardous Substances Data)

Usage

Description

CarbaMic acid, N-(4-bromo-2-nitrophenyl)-, 1,1-dimethylethyl ester, also known as tert-butyl N-(4-bromo-2-nitrophenyl)carbamate, is a chemical compound that serves as a reactant in the synthesis of selective histone deacetylase (HDAC) inhibitors. It plays a crucial role in the development of drugs targeting specific HDAC isoforms, which are important for various biological processes and have potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
CarbaMic acid, N-(4-bromo-2-nitrophenyl)-, 1,1-dimethylethyl ester is used as a reactant for the optimization of selective HDAC1/HDAC2 inhibitors. It aids in the development of drugs that can specifically target these HDAC isoforms, which are involved in the regulation of gene expression and have been implicated in various diseases, including cancer, neurological disorders, and cardiovascular diseases.
Used in Drug Synthesis:
CarbaMic acid, N-(4-bromo-2-nitrophenyl)-, 1,1-dimethylethyl ester is used in the preparation of selective HDAC inhibitors. These inhibitors have potential therapeutic applications in the treatment of various diseases by modulating the activity of specific HDAC isoforms, leading to changes in gene expression and cellular function. The development of selective HDAC inhibitors can help improve the efficacy and safety of treatments for these conditions.

Upstream product

• 88-74-4 2-nitro-aniline 
• 875-51-4 4-Bromo-2-nitroaniline 
• 131818-17-2 tert-butyl (4-bromophenyl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1228392-59-3 N-(4-bromo-2-nitrophenyl)-N-tert-butoxycarbonylcarbamic acid tert-butyl ester 

Downstream Products

• 335254-77-8 tert-butyl (3-nitro-[1, 1'-biphenyl]-4-yl)carbamate 

Relevant articles and documents

Ring size changes in the development of class I HDAC inhibitors

Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.

HDAC DEGRADER

The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may

URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES

The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autos